BioGaia ABCHIX:BIOGBS 100 Operating Margin % is 27.15% as of Mar. 2026, which is 17% below its 10-year median of 32.64. GuruFocus rates CHIX:BIOGBS with a GF Score™ of 100/100 and a GF Value™ of kr129.06. The stock has 4 warning signs investors should review. Among 955 Drug Manufacturers companies, BioGaia AB ranks better than 91.73% on this metric.
Operating Margin % is calculated as Operating Income divided by its Revenue. BioGaia AB's Operating Income for the
three
months ended in Mar. 2026 was kr101 Mil. BioGaia AB's Revenue for the
three
months ended in Mar. 2026 was kr373 Mil. Therefore, BioGaia AB's Operating Margin % for the quarter that ended in Mar. 2026 was 27.15%.
Warning Sign:
BioGaia AB operating margin has been in a 5-year decline. The average rate of decline per year is -1.8%.
The historical rank and industry rank for BioGaia AB's Operating Margin % or its related term are showing as below:
CHIX:BIOGBs'
s Operating Margin % Range Over the Past 10 Years
Min: 26.97 Med: 32.64 Max: 38.78
Current: 26.97
CHIX:BIOGBs's Operating Margin % is ranked better than 91.73% of 955
companies
in the Drug Manufacturers industry
Industry Median: 7.45
vs CHIX:BIOGBs: 26.97
BioGaia AB's 5-Year Average Operating Margin % Growth Rate was -1.80% per year.
BioGaia AB's Operating Income for the
three
months ended in Mar. 2026 was kr101 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was kr416 Mil.
BioGaia AB (CHIX:BIOGBs) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
BioGaia AB Operating Margin % Related Terms
BioGaia AB Operating Margin % Historical Data
* Premium members only.
The historical data trend for BioGaia AB's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGaia AB Operating Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's Operating Margin % distribution charts can be found below:
* The bar in red indicates where BioGaia AB's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
BioGaia AB's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioGaia AB (CHIX:BIOGBS) has a Operating Margin % of 27.15% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on BioGaia AB and its competitors. This is 17% below median its historical median of 32.64. Over the past decade, BioGaia AB's Operating Margin % has ranged from 26.97 to 38.78. According to the industry distribution chart, BioGaia AB ranks #79 out of 955 companies in the Drug Manufacturers industry, placing it in the top 8.3%.
Is BioGaia AB's Operating Margin % too high?
BioGaia AB's current Operating Margin % of 27.15% is 17% below median its 10-year median of 32.64. Over the past 10 years, this metric has ranged from a low of 26.97 to a high of 38.78. The Drug Manufacturers industry median Operating Margin % is 7.45. BioGaia AB's value of 27.15% is 264.4% above this industry median. Based on the distribution chart, BioGaia AB ranks #79 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, BioGaia AB has a GF Score™ of 100/100, reflecting its overall financial health beyond just this single metric.
How does BioGaia AB's Operating Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, BioGaia AB ranks #79 out of 955 companies for Operating Margin %. This places BioGaia AB in the top 8% of its industry — outperforming the majority of peers. The industry median Operating Margin % is 7.45. BioGaia AB's value of 27.15% is 264.4% above this benchmark. Historically, BioGaia AB's own Operating Margin % has ranged from 26.97 to 38.78 over the past decade. While the company's 10-year median is 32.64 vs. the industry median of 7.45, BioGaia AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.45, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioGaia AB's current Operating Margin % of 27.15% is 264.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on BioGaia AB and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGaia AB's current Operating Margin % is 27.15%, which is 17% below median its own 10-year median of 32.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGaia AB stock overvalued right now?
BioGaia AB (CHIX:BIOGBS) has a current Operating Margin % of 27.15%. The stock's GF Value™ is kr129.06, compared to a current price of kr120.20 — trading 6.9% below its estimated fair value. The current Operating Margin % is 27.15%, which is 17% below median its 10-year median of 32.64 and 264.4% above the Drug Manufacturers industry median of 7.45. BioGaia AB's overall GF Score™ is 100/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For BioGaia AB (CHIX:BIOGBS), the current Operating Margin % is 27.15% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGaia AB (CHIX:BIOGBS) Overvalued in 2026?
Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued.
The current stock price of kr120.20 is trading 6.9% below its estimated GF Value™ of kr129.06.
Key valuation signals for CHIX:BIOGBS:
Operating Margin %: 27.15% (17% below median its 10-year median of 32.64)
GF Value™: kr129.06 vs. price of kr120.20 (6.9% below fair value)
Industry Position: 264.4% above the Drug Manufacturers median (#79 of 955)
No single metric tells the full story. See the CHIX:BIOGBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score
Get the complete analysis for CHIX:BIOGBS
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:BIOGBS has been successfully added to your 
